<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2518383895-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2518383895-430x241.jpg"/>
                                    
                                    <figcaption>Terremoto will now progress its next-generation AKT inhibitor programmes in oncology and rare disease. Credit: Andrii Yalanskyi / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                        
<p>Terremoto Biosciences has closed a Series C financing round worth $108m, which will allow the company to usher its range of AKT-1 selective inhibitors through early clinical development across multiple rare diseases and cancer.</p>



<p>The California-based biotech secured this funding from several new and existing investors, including industry giants like Novo Holdings, OrbiMed and Third Rock Ventures, as well as RA Capital Management, Cormorant Asset Management and BeOne Medicines.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen recepto... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>Immuno-oncology in Pharmaceuticals: Cancer radiotherapy </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>With this cash in hand, Terremoto will now advance its AKT-1-selective inhibitors through Phase I, with a specific focus on oncological indications like hormone receptor (HR)-positive breast cancer, as well as rare bleeding disorders, hereditary haemorrhagic telangiectasia (HHT).</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>The jewel in Terremoto’s oncology crown and its most developed asset is its selective ATK1 blocker, TER-2031, which the company is currently evaluating in a first-in-human Phase I trial (NCT07109726). This study is exploring the drug’s safety and efficacy in solid tumours harbouring PIK3CA, AKT, or PTEN mutations – incorporating patients with indications like breast, ovarian, squamous head and neck and endometrial cancer, as per ClinicalTrials.gov.</p>



<p>Alongside its efforts in oncology, Terremoto hopes to take TER-4480, another ATK1 inhibitor, to the clinic in HHT later in 2026. Regulators are yet to approve any therapies for this inherited bleeding disorder, which impacts around 1.4 million people worldwide, as per Cure HHT. This makes it the second most common bleeding disorder in the US after Von Willebrand disease.</p>



<h2 id="h-making-akts-more-tolerable">Making AKTs more tolerable</h2>



<p>In November 2023, AstraZeneca notched a milestone by becoming the first company to secure approval for an AKT inhibitor, Truqap (capivasertib), which is now available to patients with HR-positive, HER2-negative advanced breast cancer.</p>



<p>While the non-selective AKT1, 2 and 3 blocker has demonstrated its potential in multiple solid tumour indications and has become one of AstraZeneca’s flagship oncology products, it can cause significant side effects. Upon treatment, some patients experience glucose dysregulation, as well as increased susceptibility to infections and liver toxicity.</p>



<p>According to Terremoto, side effects associated with AKT inhibitors are generally linked to AKT2. This led the company to theorise that an AKT1-selective therapy could overcome the toxicity hurdles associated with this drug class – offering a more tolerable therapy for patients.</p><div id="slot-two"></div>



<p>Terremoto is not the only biotech attempting to harness a next-generation AKT approach, as Atavistik Bio recently dosed its first subject in a Phase I trial on its selective allosteric AKT1 E17K blocker, ATV-1601, in adults with solid tumours.</p>



<p>According to GlobalData’s Pharmaceutical Intelligence Center, there are 37 ongoing clinical trials evaluating AKT inhibitors in Phase I-III.</p>



<p>GlobalData is the parent company of<em> Pharmaceutical Technology</em>.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

TBIO

<p>Terremoto Biosciences has raised $108 million in a Series C financing round to advance its AKT-1 selective inhibitors for cancer and rare diseases. The funding, sourced from investors including Novo Holdings and OrbiMed, will support early clinical development, focusing on hormone receptor-positive breast cancer and hereditary hemorrhagic telangiectasia (HHT). Terremoto's lead asset, TER-2031, is currently in a Phase I trial for solid tumors with specific mutations. The company aims to provide a more tolerable treatment option compared to existing AKT inhibitors, which can cause significant side effects.</p>

Pharmaceutical Technology

Telesis Bio

MBX Biosciences

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Health Equip

iShares Global Healthcare

Health Care Select Sector SPDR

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Terremoto wins $108m in Series C to drive cancer and rare disease programmes